Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07346287 · ClinicalTrials.gov registry record · Phase 4
ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy
A Phase 4 study of Vaginal Atrophy and Atrophic Vaginitis, sponsored by Stratpharma.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07346287 is a Phase 4 study of Vaginal Atrophy and Atrophic Vaginitis that is actively recruiting participants, run by Stratpharma. The registered enrollment target is 10 participants, below the 355-participant average among 9 other Vaginal Atrophy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07346287, a Phase 4 study of Vaginal Atrophy and Atrophic Vaginitis, is actively recruiting participants, sponsored by Stratpharma.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Vaginal atrophy patients receiving vaginal laser therapy will be treated with daily 7-0940® following a laser session to evaluate the safety and efficacy of the product as an adjunct treatment. Clinical outcomes will be assessed using validated investigator- and patient-reported measures, with safety and symptom progression monitored throughout the study.
Conditions Studied
Interventions
- DEVICE 7-940
Study Locations (1)
California
- Orange Coast Women's Medical Group - Laguna Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-08-13 |
| Est. Completion | 2026-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07346287
The ClinicalTrials.gov registry entry for NCT07346287 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 355-participant average among 9 other Vaginal Atrophy trials with a reported enrollment target (97% lower). The listed sponsor is Stratpharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Vaginal Atrophy appearing as the primary indexed condition, and to 1 intervention - of which 7-940 is the first listed.
NCT07346287 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07346287 about?
NCT07346287 is a clinical study titled "ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy". Vaginal atrophy patients receiving vaginal laser therapy will be treated with daily 7-0940® following a laser session to evaluate the safety and efficacy of the product as an adjunct treatment. Clinical outcomes will be assessed using validated investigator- and patient-reported measures, with safet...
What is the current status of trial NCT07346287?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2025-08-13. Estimated completion is 2026-04.
What conditions does trial NCT07346287 study?
This clinical trial studies the following conditions: Vaginal Atrophy, Atrophic Vaginitis, Genitourinary Syndrome of Menopause (GSM).
What interventions are being tested in trial NCT07346287?
The interventions under investigation include: 7-940 (DEVICE).
Who is sponsoring clinical trial NCT07346287?
This trial is sponsored by Stratpharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07346287 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaginal Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo
RECRUITING · Phase 4
-
Postpartum Vaginal Estrogen for Breastfeeding Patients
RECRUITING · Phase 4
-
Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy
COMPLETED · Phase 4
-
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
RECRUITING · NA
-
PRP Injections for Genitourinary Syndrome of Menopause
ACTIVE NOT RECRUITING · NA
-
Topical DHEA Against Vaginal Atrophy
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.